Bristol-Myers Squibb Co (BSP:BMYB34) EPS (Basic): R$19.08 (TTM As of Mar. 2026)


BSP:BMYB34 Bristol-Myers Squibb Co BSP:BMYB34
71 GF Score
Price R$287.84
GF Value R$274.39
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co EPS (Basic)?

Bristol-Myers Squibb Co BSP:BMYB34 +2.49% 71 EPS (Basic) is R$19.08 as of Mar. 2026. GuruFocus rates BSP:BMYB34 with a GF Score™ of 71/100 and a GF Value™ of R$274.39 (Fairly Valued). The stock has 4 warning signs investors should review.

Bristol-Myers Squibb Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was R$6.85. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was R$19.08.

Bristol-Myers Squibb Co's EPS (Diluted) for the three months ended in Mar. 2026 was R$6.85. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was R$19.08.

Bristol-Myers Squibb Co's EPS without NRI for the three months ended in Mar. 2026 was R$8.26. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 31.98.

During the past 12 months, Bristol-Myers Squibb Co's average EPS without NRIGrowth Rate was -19.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was -7.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -15.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Bristol-Myers Squibb Co's highest 3-Year average EPS without NRI Growth Rate was 36.10% per year. The lowest was -46.50% per year. And the median was 9.75% per year.

Bristol-Myers Squibb Co  (BSP:BMYB34) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Bristol-Myers Squibb Co EPS (Basic) Related Terms

Bristol-Myers Squibb Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co EPS (Basic) Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.81 15.58 19.01 -26.91 18.93

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.97 3.55 5.79 2.89 6.85
BSP:BMYB34
71GF Score
Bristol-Myers Squibb Co BSP:BMYB34
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Bristol-Myers Squibb Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(38484.508-0)/2034.000
=18.92

Bristol-Myers Squibb Co's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(13999.639-0)/2038.000
=6.87

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$19.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of R$19.08 mean?
Bristol-Myers Squibb Co (BSP:BMYB34) has a EPS (Basic) of R$19.08 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's EPS (Basic) too high?
Bristol-Myers Squibb Co's current EPS (Basic) is R$19.08. Overall, Bristol-Myers Squibb Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's EPS (Basic) compare to PFE and GILD?
Bristol-Myers Squibb Co's EPS (Basic) of R$19.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current EPS (Basic) is R$19.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BSP:BMYB34) is currently considered Fairly Valued. The stock's GF Value™ is R$274.39, compared to a current price of R$287.84 — trading 4.9% above its estimated fair value. The current EPS (Basic) is R$19.08. Bristol-Myers Squibb Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BSP:BMYB34), the current EPS (Basic) is R$19.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (BSP:BMYB34) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of R$287.84 is trading 4.9% above its estimated GF Value™ of R$274.39. GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.

Key valuation signals for BSP:BMYB34:

  • EPS (Basic): R$19.08
  • GF Value™: R$274.39 vs. price of R$287.84 (4.9% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the BSP:BMYB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
71GF Score

Get the complete analysis for BSP:BMYB34

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$287.84
Price
R$274.39
GF Value